ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification.
Molekulargewicht:
384.43
CAS Nummer:
[3054692-62-2]
Formel:
C19H24N6O3
Target-Kategorie:
CDK
T204836
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten